miR-16 has been identified as a tumor suppressor, which inhibits cancer cell growth and proliferation in vitro via the insulin-like growth factor 1 receptor, the Raf1/mitogen-activated protein kinase kinase 1/2/ERK 1/2 and the p53/survivin signaling pathways (29,30). Here, MAP3K1 is linked to neoplasm.